Cargando…
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses
BACKGROUND: Longer-term humoral responses to 2-dose coronavirus disease 2019 (COVID-19) vaccines remain incompletely characterized in people living with human immunodeficiency virus (HIV) (PLWH), as do initial responses to a third dose. METHODS: We measured antibodies against the severe acute respir...
Ejemplares similares
-
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses
por: Lapointe, Hope R., et al.
Publicado: (2022) -
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy
por: Lapointe, Hope R., et al.
Publicado: (2023) -
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
por: Brumme, Zabrina L., et al.
Publicado: (2021) -
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy
por: Brumme, Zabrina L., et al.
Publicado: (2022) -
Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine
por: Brockman, Mark A., et al.
Publicado: (2021)